Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Identification of Graphic Markers of Neurocognitive Disorders Such as Primary Progressive Aphasia (PPA) and Early-stage Alzheimer's Disease (AD) (MG)

NCT05537688 is registered in ClinicalTrials.gov with Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal as lead sponsor.

NCT NCT05537688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05537688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Identification of Graphic Markers of Neurocognitive Disorders Such as Primary Progressive Aphasia (PPA) and Early-stage Alzheimer's Disease (AD) (MG)
Lead sponsor
Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
Phase
Observational
Overall status
Completed
Start date
June 27, 2022
Completion date
August 27, 2023
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, neurocognitive disorders, primary progressive aphasia